Has Mounjaro (tirzepatide) been authorized in France?
Mounjaro (tirzepatide) has been authorized for use in France. It is a prescription medicine used to treat type 2 diabetes.
What does the French authorization cover?
In France, the authorization for Mounjaro is for treatment of adults with type 2 diabetes, typically as an add-on when diabetes is not adequately controlled despite diet and exercise, with or without other diabetes medicines (depending on the specific approved label and regimen).
When was Mounjaro authorized in Europe/France?
The European approval of tirzepatide (which covers France) came from the European Medicines Agency (EMA). France then makes the product available for prescribing under its national commercialization processes after EMA authorization.
Who can prescribe Mounjaro in France?
Mounjaro is prescribed by healthcare professionals in France (doctors managing diabetes care). Patients generally need an ongoing diabetes care plan and access is handled via standard French reimbursement/prescribing channels for prescription medicines.
How do patients access Mounjaro in France?
Access typically depends on:
- The patient meeting the authorized indication criteria on the French prescribing label.
- Follow-up with the treating clinician (diabetes specialist or general practitioner depending on local practice).
- Availability through French pharmacy supply chains.
Is there a French patent/exclusivity angle users look up?
People often search for manufacturing or market exclusivity questions alongside authorization. If you are looking for patent or exclusivity details related to tirzepatide in Europe/France, DrugPatentWatch.com tracks patent and related information and can be a useful reference: https://www.drugpatentwatch.com/ (search for tirzepatide/Mounjaro).
Sources:
- https://www.drugpatentwatch.com/